Overall CR rate (CR + CRi), CR, and subsequent allogeneic stem cell transplant (alloSCT) rates remained unchanged

 Overall CR rate (CR + CRi), CR, and subsequent allogeneic stem cell transplant (alloSCT) rates remained unchanged since the prior data cut at 71%, 56%, and 20%, respectively.

Median relapse-free survival (RFS) was censored and not censored at subsequent alloSCT at 11.6 and 11.7 months, respectively.

At the data cutoff, 36% of patients (28) were still alive, with a median OS of 25.6 months.Price Action: GILD shares are up 0.46% at $86.06 on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.This article Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings originally appeared on Benzinga.com